Harrow Health acquires rights to surgical drug candidate in US, Canada
Click Here to Manage Email Alerts
Harrow Health has finalized an agreement to acquire commercial rights for MAQ-100 in the United States and Canada from Wakamoto Pharmaceutical, according to a press release.
MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection, is marketed in Japan as MaQaid and was originally launched for visualization during vitrectomy. It has since gained indications for the treatment of diabetic macular edema, macular edema associated with retinal vein occlusion and noninfectious uveitis, the release said.
Harrow plan to use the clinical data that supported the approval of MaQaid in Japan for a clinical program and for a new drug application submission of MAQ-100 in the U.S. for visualization during vitrectomy.
“We are indeed honored to work with our new partners at Wakamoto to bring MAQ-100 to the U.S. and Canadian markets,” Mark L. Baum, CEO of Harrow Health, said in the release. “This transaction is an excellent strategic fit with our recent commitment to expand our footprint to include retinafocused surgeons and follows our recent announcement of the acquisition of AMP100, a patented, innovative ocular surface anesthetic drug candidate.”
Harrow Health will make payments to Wakamoto based on commercial milestones. Wakamoto will retain marketing rights to MAQ-100 in other countries.
Read more about
Click Here to Manage Email Alerts